Objective. To determine the carriage rate of thrombogenic mutations (FVG1G91A, FIIG20210A, MTHFR C677T, FGB G455A, and PAI-1-6755G/4G) and to assess the hemostatic system in pregnant women with a history of nondeveloping pregnancy. Subjects and methods. In 217 pregnant women, the carriage rate of thrombogenic mutations (FV, FII, MTHFR, FBG, and PAI-1) and major hemostatic parameters were determined both in patients with third-trimester physiological pregnancy without a history of miscarriage (spontaneous, out-of-hospital or missed abortions) and in those with a bad obstetric history (a history of nondeveloping pregnancy). Results. The carriage of methylenetetrahydrofolate reductase (MTHFR) gene mutations proved to be most significant for miscarriage. There were significant hypercoagulation shifts with the enhanced activity of procoagulant factors and with decreased blood anticoagulant and fibrinolytic activities in women with a history of nondeveloping pregnancy. Conclusion. The timely detection of factors for genetic thrombophilia and pathological hypercoagulation furnishes an opportunity to make pathogenetically sound drug correction.